Spots Global Cancer Trial Database for Brain Metastases In ErbB2-Positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Brain Metastases In ErbB2-Positive Breast Cancer
Official Title: Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Study ID: NCT00437073
Conditions
Study Description
Brief Summary: This study is for patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. The study will determine how safe and effective lapatinib is when given in combination with capecitabine to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed regularly during the course of the study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Washington, District of Columbia, United States
GSK Investigational Site, Indianapolis, Indiana, United States
GSK Investigational Site, Sioux City, Iowa, United States
GSK Investigational Site, Boston, Massachusetts, United States
GSK Investigational Site, Minneapolis, Minnesota, United States
GSK Investigational Site, Rochester, Minnesota, United States
GSK Investigational Site, Albuquerque, New Mexico, United States
GSK Investigational Site, Cary, North Carolina, United States
GSK Investigational Site, Portland, Oregon, United States
GSK Investigational Site, Philadelphia, Pennsylvania, United States
GSK Investigational Site, Pittsburgh, Pennsylvania, United States
GSK Investigational Site, Spartanburg, South Carolina, United States
GSK Investigational Site, Dallas, Texas, United States
GSK Investigational Site, Salzburg, , Austria
GSK Investigational Site, Vienna, , Austria
GSK Investigational Site, Bruxelles, , Belgium
GSK Investigational Site, Edmonton, Alberta, Canada
GSK Investigational Site, Vancouver, British Columbia, Canada
GSK Investigational Site, Quebec, , Canada
GSK Investigational Site, Besançon, , France
GSK Investigational Site, Lille Cedex, , France
GSK Investigational Site, Paris Cedex 5, , France
GSK Investigational Site, Paris, , France
GSK Investigational Site, Saint-Herblain, , France
GSK Investigational Site, Muenchen, Bayern, Germany
GSK Investigational Site, Muenchen, Bayern, Germany
GSK Investigational Site, Frankfurt am Main, Hessen, Germany
GSK Investigational Site, Troisdorf, Nordrhein-Westfalen, Germany
GSK Investigational Site, Bremen, , Germany
GSK Investigational Site, Heraklion, Crete, , Greece
GSK Investigational Site, Neo Faliro, , Greece
GSK Investigational Site, Petach Tikva, , Israel
GSK Investigational Site, Ramat Gan, , Israel
GSK Investigational Site, Zrifin, , Israel
GSK Investigational Site, Milano, Lombardia, Italy
GSK Investigational Site, Perugia, Umbria, Italy
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Hospitalet de Llobregat, Barcelona, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Pamplona, , Spain
GSK Investigational Site, Santiago de Compostela, , Spain
GSK Investigational Site, Valencia, , Spain
GSK Investigational Site, Uppsala, , Sweden
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
